We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Smith+Nephew Launches LYNX COBLATION Wand for ENT Airway Surgery
Read MoreHide Full Article
Key Takeaways
Smith Nephew launched the LYNX Wand, a single-device solution for ENT airway procedures.
The wand combines fine dissection, rapid tissue debulking and integrated hemostasis.
FDA clearance in March 2026 preceded launch, while shares gained 3.3% after the announcement.
Smith+Nephew (SNN - Free Report) recently announced the commercial launch of the LYNX COBLATION Laryngeal Wand, a multipurpose surgical device designed specifically for ENT surgeons performing airway procedures. Developed with insights from laryngologists, the wand combines fine tissue dissection and rapid mass debulking in a single instrument, enabling surgeons to treat anatomy from the supraglottis to the trachea while operating at low temperatures.
Per management, early feedback from surgeons using the LYNX COBLATION Laryngeal Wand has been encouraging. The product was developed based on feedback from ENT surgeons to address an unmet need for a versatile, single-device solution that streamlines airway procedures.
Dr. Priya Krishna, professor at Loma Linda University Health System, Department of Otolaryngology-Head and Neck Surgery, noted that the LYNX Wand provides efficient tissue removal, while its extended length enhances versatility.
Likely Trend of SNN Stock Following the News
Following the announcement, shares of SNN gained 3.3% at yesterday’s close. Year to date, shares of the company have lost 6.1% compared with the industry’s 23.7% decline. The S&P 500 has risen 10.9% in the same timeframe.
Smith+Nephew is likely to benefit from the launch of the LYNX COBLATION Laryngeal Wand as it expands the company’s ENT portfolio with a versatile solution for airway procedures. The launch shows Smith+Nephew’s commitment to innovation in ENT surgery by introducing a device that combines multiple surgical functions into a single platform. As surgeons seek technologies that improve procedural efficiency, the LYNX Wand could support broader clinical adoption and contribute to the company’s growth in the ENT market.
SNN currently has a market capitalization of $12.60 billion.
Image Source: Zacks Investment Research
More on the LYNX COBLATION Laryngeal Wand
The LYNX COBLATION Laryngeal Wand is the latest addition to Smith+Nephew’s COBLATION technology portfolio. COBLATION is an ENT Technology backed by more than two decades of clinical use and over 240 peer-reviewed publications. Prior to this launch, the company offered the PROCISE LW and PROCISE MLW Laryngeal Wands for bulky lesion removal and precise treatment of laryngeal lesions.
Building on these capabilities, the LYNX COBLATION Laryngeal Wand combines fine dissection, rapid tissue debulking and integrated hemostasis in a single instrument. The device leverages COBLATION technology for precise soft-tissue ablation, resection, coagulation and hemostasis while operating at lower temperatures than conventional electrocautery or CO2/KTP laser systems, helping reduce the risk of airway fire.
The device offers several features to improve surgical performance, including a 25 cm working length for enhanced anatomical reach, a malleable shaft that adapts to varying patient anatomies and the ability to perform radial incisions across a full 360 degrees. Surgeons can also choose from three ablation settings to balance rapid tissue debulking with precise lesion creation. Its self-clearing mechanism helps prevent clogging during procedures, supporting an uninterrupted surgical workflow.
The LYNX COBLATION Laryngeal Wand received FDA 510(k) clearance in March 2026, marking an important regulatory milestone ahead of its commercial launch and further expanding Smith+Nephew’s portfolio of advanced ENT surgical solutions.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the ENT devices market is valued at $28.17 billion in 2026 and is expected to witness a CAGR of 4.2% through 2034.
Factors like therising geriatric population, the increasing prevalence of ENT-related disorders and the expanding penetration of minimally invasive ENT procedures are boosting the market’s growth.
Other News
Smith+Nephew recently announced the U.S. launch of its next-generation LEAF Patient Monitoring System, a data-driven pressure injury prevention platform designed to help healthcare providers reduce hospital-acquired pressure injuries. The system uses a wearable sensor to monitor patient mobility and deliver real-time turn status updates, supporting improved workflow efficiency, patient repositioning and adherence to care protocols.
West Pharmaceutical reported first-quarter 2026 earnings per share of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
View the Zacks #1 Rank List
Image: Bigstock
Smith+Nephew Launches LYNX COBLATION Wand for ENT Airway Surgery
Key Takeaways
Smith+Nephew (SNN - Free Report) recently announced the commercial launch of the LYNX COBLATION Laryngeal Wand, a multipurpose surgical device designed specifically for ENT surgeons performing airway procedures. Developed with insights from laryngologists, the wand combines fine tissue dissection and rapid mass debulking in a single instrument, enabling surgeons to treat anatomy from the supraglottis to the trachea while operating at low temperatures.
Per management, early feedback from surgeons using the LYNX COBLATION Laryngeal Wand has been encouraging. The product was developed based on feedback from ENT surgeons to address an unmet need for a versatile, single-device solution that streamlines airway procedures.
Dr. Priya Krishna, professor at Loma Linda University Health System, Department of Otolaryngology-Head and Neck Surgery, noted that the LYNX Wand provides efficient tissue removal, while its extended length enhances versatility.
Likely Trend of SNN Stock Following the News
Following the announcement, shares of SNN gained 3.3% at yesterday’s close. Year to date, shares of the company have lost 6.1% compared with the industry’s 23.7% decline. The S&P 500 has risen 10.9% in the same timeframe.
Smith+Nephew is likely to benefit from the launch of the LYNX COBLATION Laryngeal Wand as it expands the company’s ENT portfolio with a versatile solution for airway procedures. The launch shows Smith+Nephew’s commitment to innovation in ENT surgery by introducing a device that combines multiple surgical functions into a single platform. As surgeons seek technologies that improve procedural efficiency, the LYNX Wand could support broader clinical adoption and contribute to the company’s growth in the ENT market.
SNN currently has a market capitalization of $12.60 billion.
Image Source: Zacks Investment Research
More on the LYNX COBLATION Laryngeal Wand
The LYNX COBLATION Laryngeal Wand is the latest addition to Smith+Nephew’s COBLATION technology portfolio. COBLATION is an ENT Technology backed by more than two decades of clinical use and over 240 peer-reviewed publications. Prior to this launch, the company offered the PROCISE LW and PROCISE MLW Laryngeal Wands for bulky lesion removal and precise treatment of laryngeal lesions.
Building on these capabilities, the LYNX COBLATION Laryngeal Wand combines fine dissection, rapid tissue debulking and integrated hemostasis in a single instrument. The device leverages COBLATION technology for precise soft-tissue ablation, resection, coagulation and hemostasis while operating at lower temperatures than conventional electrocautery or CO2/KTP laser systems, helping reduce the risk of airway fire.
The device offers several features to improve surgical performance, including a 25 cm working length for enhanced anatomical reach, a malleable shaft that adapts to varying patient anatomies and the ability to perform radial incisions across a full 360 degrees. Surgeons can also choose from three ablation settings to balance rapid tissue debulking with precise lesion creation. Its self-clearing mechanism helps prevent clogging during procedures, supporting an uninterrupted surgical workflow.
The LYNX COBLATION Laryngeal Wand received FDA 510(k) clearance in March 2026, marking an important regulatory milestone ahead of its commercial launch and further expanding Smith+Nephew’s portfolio of advanced ENT surgical solutions.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the ENT devices market is valued at $28.17 billion in 2026 and is expected to witness a CAGR of 4.2% through 2034.
Factors like therising geriatric population, the increasing prevalence of ENT-related disorders and the expanding penetration of minimally invasive ENT procedures are boosting the market’s growth.
Other News
Smith+Nephew recently announced the U.S. launch of its next-generation LEAF Patient Monitoring System, a data-driven pressure injury prevention platform designed to help healthcare providers reduce hospital-acquired pressure injuries. The system uses a wearable sensor to monitor patient mobility and deliver real-time turn status updates, supporting improved workflow efficiency, patient repositioning and adherence to care protocols.
Smith & Nephew SNATS, Inc. Price
Smith & Nephew SNATS, Inc. price | Smith & Nephew SNATS, Inc. Quote
SNN’s Zacks Rank & Key Picks
Currently, SNN has a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported first-quarter 2026 earnings per share of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.